Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | LMNA | P02545 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29803356 | 1.00 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL1612901 | 0.91 | LMNA (0.67) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL10036437 | 0.90 | MAPT (0.55) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL15244321 | 0.90 | MAPT (0.55) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL26464995 | 0.90 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL25403910 | 0.88 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL855350 | 0.87 | MAPT (0.61) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL15244350 | 0.87 | MAPT (0.50) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL1810972 | 0.86 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL31639389 | 0.86 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230203042-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| CN-115124590-A | PROTAC compound for targeted degradation of FLT3-ITD mutant protein and preparation method and application thereof | 武汉大学中南医院 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-112334451-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | ALDH1A1 2869/4885LMNA 3549/4885MAPT 4445/4885 |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | ALDH1A1 2534/4885LMNA 2478/4885MAPT 3390/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885LMNA 3004/4885MAPT 3156/4885 |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | ALDH1A1 1432/4885LMNA 4565/4885MAPT 1593/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | ALDH1A1 2992/4885LMNA 3004/4885MAPT 3156/4885 |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | ALDH1A1 1940/4885LMNA 3631/4885MAPT 3728/4885 |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | ALDH1A1 1692/4885LMNA 2527/4885MAPT 4260/4885 |
| US-20230203042-A1 | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, BTK, LCK | ALDH1A1 2839/4885LMNA 4829/4885MAPT 4522/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | ALDH1A1 1113/4885LMNA 3852/4885MAPT 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.